Encompass Health (NYSE:EHC) Given New $66.00 Price Target at Royal Bank of Canada – MarketBeat

Encompass Health (NYSE:EHC – Get Rating) had its price target decreased by stock analysts at Royal Bank of Canada from $82.00 to $66.00 in a note issued to investors on Wednesday, The Fly reports. Royal Bank of Canada’s price target indicates a potential upside of 30.38% from the stock’s previous close.

A number of other research firms have also recently issued reports on EHC. StockNews.com cut shares of Encompass Health from a “buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Encompass Health from $80.00 to $62.00 in a research report on Wednesday, August 3rd. Raymond James lowered their target price on shares of Encompass Health from $70.00 to $65.00 and set a “strong-buy” rating on the stock in a report on Thursday, August 4th. Truist Financial lowered their target price on shares of Encompass Health from $75.00 to $65.00 and set a “buy” rating on the stock in a report on Monday, August 8th. Finally, BMO Capital Markets lowered their target price on shares of Encompass Health from $83.00 to $65.00 and set an “outperform” rating on the stock in a report on Thursday, August 4th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $70.10.

Encompass Health Stock Down 1.3 %

Shares of NYSE:EHC opened at $50.62 on Wednesday. The company has a fifty day moving average of $51.73 and a 200-day moving average of $61.64. The company has a market capitalization of $5.05 billion, a PE ratio of 15.48, a price-to-earnings-growth ratio of 2.62 and a beta of 0.91. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.24 and a current ratio of 1.24. Encompass Health has a 52-week low of $44.33 and a 52-week high of $81.45.

Encompass Health (NYSE:EHC – Get Rating) last posted its quarterly earnings data on Monday, August 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.08). The company had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.34 billion. Encompass Health had a net margin of 6.22% and a return on equity of 16.20%. The business’s revenue for the quarter was up 3.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.17 earnings per share. On average, equities analysts predict that Encompass Health will post 2.67 EPS for the current fiscal year.

Insider Activity

In related news, CEO Mark J. Tarr sold 20,449 shares of the company’s stock in a transaction dated Wednesday, August 17th. The shares were sold at an average price of $53.25, for a total value of $1,088,909.25. Following the completion of the sale, the chief executive officer now directly owns 440,895 shares of the company’s stock, valued at $23,477,658.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.70% of the company’s stock.

Institutional Trading of Encompass Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Eagle Bay Advisors LLC boosted its stake in Encompass Health by 137.5% during the 2nd quarter. Eagle Bay Advisors LLC now owns 1,019 shares of the company’s stock worth $57,000 after purchasing an additional 590 shares during the last quarter. Dean Investment Associates LLC increased its stake in Encompass Health by 11.8% during the second quarter. Dean Investment Associates LLC now owns 46,066 shares of the company’s stock worth $2,582,000 after purchasing an additional 4,872 shares during the period. Goldman Sachs Group Inc. raised its holdings in Encompass Health by 4.0% in the second quarter. Goldman Sachs Group Inc. now owns 280,460 shares of the company’s stock valued at $15,720,000 after acquiring an additional 10,907 shares in the last quarter. United Services Automobile Association acquired a new stake in Encompass Health in the second quarter valued at approximately $596,000. Finally, Woodline Partners LP acquired a new stake in Encompass Health during the second quarter worth approximately $2,857,000. 91.70% of the stock is currently owned by institutional investors and hedge funds.

About Encompass Health

(Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Encompass Health, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Encompass Health wasn’t on the list.

While Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: marketbeat.com